» Articles » PMID: 34050619

Patterns of Acute Decompensation in Hospitalized Patients with Cirrhosis and Course of Acute-on-chronic Liver Failure

Abstract

Introduction: Recently, based on data from the PREDICT study, the European Foundation for the Study of Chronic Liver Failure (EF-CLIF) consortium proposed pathophysiological/prognostic groups in hospitalized patients with cirrhosis: stable decompensated cirrhosis (SDC), unstable decompensated cirrhosis (UDC), pre-acute-on-chronic liver failure (pre-ACLF), and ACLF. We evaluated the outcomes of these subgroups in a real-life cohort of hospitalized patients with cirrhosis.

Methods: Patients with cirrhosis developing first AD between 09/2010 and 12/2017 at the Vienna General Hospital were evaluated for this retrospective analysis.

Results: Two hundred and ten patients with cirrhosis (aged 57.6 ± 11.8 years) including n = 45 (21.4%) SDC, n = 100 (47.6%) UDC, n = 28 (13.3%) pre-ACLF, and n = 37 (17.6%) with ACLF were considered. The proposed AD subgroups discriminated between patients with favorable (1-year mortality: SDC: 6.7% and UDC: 19.6%) and dismal prognosis (90-day mortality: pre-ACLF: 42.9%). Interestingly, systemic inflammation gradually increased (e.g., C-reactive protein, SDC: 0.9 mg/dl, vs. UDC: 2.0 mg/dl vs. pre-ACLF: 3.2 mg/dl, p < 0.001) while renal function was progressively deteriorating (creatinine levels, SDC: 0.8 mg/dl vs. UDC: 0.9 mg/dl vs. pre-ACLF: 1.2 mg/dl, p < 0.001) across prognostic subgroups in patients with cirrhosis.

Discussion: The recently proposed pathophysiological/prognostic EF-CLIF subgroups are also reproduceable in a real-life cohort of cirrhotic patients. As ACLF is a common and important complication, patients at risk of pre-ACLF at index AD should be evaluated and if disease proceeds, been treated early and aggressively to avoid excessive mortality.

Citing Articles

Use of the CytoSorb adsorber in patients with acute-on-chronic liver failure.

Haselwanter P, Scheiner B, Balcar L, Semmler G, Riedl-Wewalka M, Schmid M Sci Rep. 2024; 14(1):11309.

PMID: 38760460 PMC: 11101465. DOI: 10.1038/s41598-024-61658-3.


Acute and non-acute decompensation of liver cirrhosis (47/130).

Schulz M, Angeli P, Trebicka J Liver Int. 2024; 45(3):e15861.

PMID: 38426268 PMC: 11815624. DOI: 10.1111/liv.15861.


Acute decompensation of cirrhosis versus acute-on-chronic liver failure: What are the clinical implications?.

Xu M, Chen Y, Artru F United European Gastroenterol J. 2024; 12(2):194-202.

PMID: 38376886 PMC: 10954432. DOI: 10.1002/ueg2.12538.


The Clinical Courses and Prognosis of Cirrhotic Patients after First Acute Decompensation: Prospective Cohort Study.

Kim J, Kim S, Song D, Kim H, Yoon E, Kang S Diagnostics (Basel). 2024; 14(1).

PMID: 38201324 PMC: 10795755. DOI: 10.3390/diagnostics14010014.


Lower free triiodothyronine (fT3) levels in cirrhosis are linked to systemic inflammation, higher risk of acute-on-chronic liver failure, and mortality.

Hartl L, Simbrunner B, Jachs M, Wolf P, Bauer D, Scheiner B JHEP Rep. 2023; 6(1):100954.

PMID: 38125301 PMC: 10733101. DOI: 10.1016/j.jhepr.2023.100954.


References
1.
Trebicka J, Sundaram V, Moreau R, Jalan R, Arroyo V . Liver Transplantation for Acute-on-Chronic Liver Failure: Science or Fiction?. Liver Transpl. 2020; 26(7):906-915. DOI: 10.1002/lt.25788. View

2.
Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C . The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol. 2020; 73(4):842-854. DOI: 10.1016/j.jhep.2020.06.013. View

3.
Piano S, Brocca A, Mareso S, Angeli P . Infections complicating cirrhosis. Liver Int. 2018; 38 Suppl 1:126-133. DOI: 10.1111/liv.13645. View

4.
Barosa R, Roque Ramos L, Patita M, Nunes G, Fonseca J . CLIF-C ACLF score is a better mortality predictor than MELD, MELD-Na and CTP in patients with Acute on chronic liver failure admitted to the ward. Rev Esp Enferm Dig. 2017; 109(6):399-405. DOI: 10.17235/reed.2017.4701/2016. View

5.
Sola E, Pose E, Campion D, Piano S, Roux O, Simon-Talero M . Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. J Hepatol. 2020; 74(1):200-219. DOI: 10.1016/j.jhep.2020.08.009. View